AU2008231723B2 - Nucleic acids - Google Patents

Nucleic acids Download PDF

Info

Publication number
AU2008231723B2
AU2008231723B2 AU2008231723A AU2008231723A AU2008231723B2 AU 2008231723 B2 AU2008231723 B2 AU 2008231723B2 AU 2008231723 A AU2008231723 A AU 2008231723A AU 2008231723 A AU2008231723 A AU 2008231723A AU 2008231723 B2 AU2008231723 B2 AU 2008231723B2
Authority
AU
Australia
Prior art keywords
epitope
nucleic acid
responses
immunobody
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2008231723A
Other languages
English (en)
Other versions
AU2008231723A1 (en
Inventor
Linda Gillian Durrant
Rachael Louise Metheringham
Victoria Anne Pudney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scancell Ltd
Original Assignee
Scancell Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scancell Ltd filed Critical Scancell Ltd
Publication of AU2008231723A1 publication Critical patent/AU2008231723A1/en
Application granted granted Critical
Publication of AU2008231723B2 publication Critical patent/AU2008231723B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2008231723A 2007-03-28 2008-03-28 Nucleic acids Active AU2008231723B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0706070.0A GB0706070D0 (en) 2007-03-28 2007-03-28 Nucleic acids
GB0706070.0 2007-03-28
PCT/EP2008/053761 WO2008116937A2 (en) 2007-03-28 2008-03-28 Nucleic acids

Publications (2)

Publication Number Publication Date
AU2008231723A1 AU2008231723A1 (en) 2008-10-02
AU2008231723B2 true AU2008231723B2 (en) 2013-05-16

Family

ID=38050410

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008231723A Active AU2008231723B2 (en) 2007-03-28 2008-03-28 Nucleic acids

Country Status (16)

Country Link
US (1) US8742088B2 (enExample)
EP (2) EP2134357B1 (enExample)
JP (1) JP5415399B2 (enExample)
KR (4) KR20150013357A (enExample)
CN (2) CN103667304B (enExample)
AT (1) ATE529128T1 (enExample)
AU (1) AU2008231723B2 (enExample)
BR (1) BRPI0808599A2 (enExample)
CA (1) CA2681531C (enExample)
DK (2) DK2193803T3 (enExample)
ES (2) ES2375463T3 (enExample)
GB (1) GB0706070D0 (enExample)
PL (1) PL2134357T3 (enExample)
PT (2) PT2193803E (enExample)
WO (1) WO2008116937A2 (enExample)
ZA (1) ZA200907242B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0706070D0 (en) 2007-03-28 2007-05-09 Scancell Ltd Nucleic acids
GB201214007D0 (en) 2012-08-07 2012-09-19 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
EP3253419A1 (en) 2015-02-02 2017-12-13 The University of Birmingham Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes
WO2017210149A1 (en) * 2016-05-31 2017-12-07 Igc Bio, Inc. Compositions and methods for generating an antibody library
US11419928B2 (en) 2017-10-25 2022-08-23 The Johns Hopkins University Methods and compositions for treating cancer
GB201815041D0 (en) 2018-09-14 2018-10-31 Scancell Ltd Epitopes
WO2021195089A1 (en) 2020-03-23 2021-09-30 Sorrento Therapeutics, Inc. Fc-coronavirus antigen fusion proteins, and nucleic acids, vectors, compositions and methods of use thereof
CN111423504B (zh) * 2020-04-17 2021-03-26 安徽高安生物医学科技有限公司 黑色素瘤特异性抗原肽、肽复合物以及人工抗原呈递细胞
BR112023002195A2 (pt) 2020-08-26 2023-03-14 Scancell Ltd Ácido nucleico que codifica um polipeptídeo, vetor, peptídeo, e composição de vacina
GB202314361D0 (en) * 2023-09-19 2023-11-01 Scancell Ltd Vaccine compositions and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999025379A1 (en) * 1997-11-14 1999-05-27 Euro-Celtique, S.A. Modified antibodies with enhanced ability to elicit an anti-idiotype response

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5969109A (en) * 1990-02-28 1999-10-19 Bona; Constantin Chimeric antibodies comprising antigen binding sites and B and T cell epitopes
ATE204300T1 (de) 1994-05-13 2001-09-15 Biovation Ltd Zielzellen-bindende chimäre peptide
CA2195642A1 (en) * 1994-07-27 1996-02-08 Andreas Suhrbier Polyepitope vaccines
US5698679A (en) * 1994-09-19 1997-12-16 National Jewish Center For Immunology And Respiratory Medicine Product and process for targeting an immune response
AUPO784197A0 (en) * 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
EP1181320B1 (en) * 1999-04-27 2011-03-09 Nevagen LLC Somatic transgene immunization and related methods
US7067110B1 (en) * 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
GB0102145D0 (en) * 2001-01-26 2001-03-14 Scancell Ltd Substances
GB0111628D0 (en) 2001-05-11 2001-07-04 Scancell Ltd Binding member
AU2002331704A1 (en) * 2001-08-22 2003-03-10 The Government Of The United States Of America, Represented By The Secretary, Department Of Health A Peptides of melanoma antigen and their use in diagnostic, prophylactic and therapeutic methods
EP1556072B1 (en) * 2002-09-17 2010-05-19 Antigen Express, Inc. Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES
GB0706070D0 (en) 2007-03-28 2007-05-09 Scancell Ltd Nucleic acids

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999025379A1 (en) * 1997-11-14 1999-05-27 Euro-Celtique, S.A. Modified antibodies with enhanced ability to elicit an anti-idiotype response

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZAGHOUANI, H et al, INTER. REV. IMMUNOL (1993), Vol 10, pages 265-278 *

Also Published As

Publication number Publication date
GB0706070D0 (en) 2007-05-09
KR20170040387A (ko) 2017-04-12
EP2134357A2 (en) 2009-12-23
JP2010522550A (ja) 2010-07-08
CA2681531A1 (en) 2008-10-02
US8742088B2 (en) 2014-06-03
DK2193803T3 (da) 2012-02-13
WO2008116937A2 (en) 2008-10-02
PL2134357T3 (pl) 2018-03-30
CN101678092B (zh) 2014-04-02
CN103667304A (zh) 2014-03-26
KR20150013357A (ko) 2015-02-04
EP2193803B1 (en) 2011-10-19
KR101729458B1 (ko) 2017-04-21
CA2681531C (en) 2017-11-28
WO2008116937A3 (en) 2009-01-22
ATE529128T1 (de) 2011-11-15
PT2193803E (pt) 2012-01-16
BRPI0808599A2 (pt) 2019-01-08
EP2134357B1 (en) 2017-05-31
JP5415399B2 (ja) 2014-02-12
ZA200907242B (en) 2010-11-24
KR20100015699A (ko) 2010-02-12
PT2134357T (pt) 2017-08-29
ES2638188T3 (es) 2017-10-19
EP2193803A1 (en) 2010-06-09
DK2134357T3 (en) 2017-09-11
ES2375463T3 (es) 2012-03-01
CN103667304B (zh) 2018-02-02
US20100260806A1 (en) 2010-10-14
CN101678092A (zh) 2010-03-24
KR20160091458A (ko) 2016-08-02
AU2008231723A1 (en) 2008-10-02

Similar Documents

Publication Publication Date Title
AU2008231723B2 (en) Nucleic acids
EP1616579B1 (en) CD40 binding molecules and CTL peptides for treating tumors
Njongmeta et al. CD205 antigen targeting combined with dendritic cell recruitment factors and antigen-linked CD40L activation primes and expands significant antigen-specific antibody and CD4+ T cell responses following DNA vaccination of outbred animals
SK782002A3 (en) FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
TW202039587A (zh) 供合成胜肽免疫原作為免疫刺激劑的人工混雜t輔助細胞抗原決定位
Metheringham et al. Antibodies designed as effective cancer vaccines
CN109929037B (zh) 针对程序性死亡配体的结合物及其应用
SK14832001A3 (sk) Analóg interleukínu 5, fragment nukleovej kyseliny, vektor, bunka, prípravky a použitie
CA2421274A1 (en) Method for down-regulating ige
US20230117803A1 (en) Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
WO2009003889A2 (en) Immunogenic analogues of rankl
WO2022161598A1 (en) Antibodies broadly targeting coronaviruses and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)